August 2007
ICIS Chemical Business;8/20/2007, Vol. 272 Issue 7, p1
Trade Publication
The article focuses on the topics discussed in the August 16, 1882 issue and the August 16, 1982 issue of the journal. In the 1882 issue, the effect of a change of barometrical pressure on the flashing point of refined petroleum was discussed. It was stated that for each inch of diminished pressure, the flashing point is lowered two degrees. The 1982 issue discussed how the use of phenacetin in pain relief medications was banned by the U.S. Food and Drug Administration due to side effects.


Related Articles

  • Rilonacept for Colchicine-Resistant or -Intolerant Familial Mediterranean Fever. Hashkes, Philip J.; Spalding, Steven J.; Giannini, Edward H.; Huang, Bin; Johnson, Anne; Park, Grace; Barron, Karyl S.; Weisman, Michael H.; Pashinian, Noune; Reiff, Andreas O.; Samuels, Jonathan; Wright, Dowain A.; Kastner, Daniel L.; Lovell, Daniel J. // Annals of Internal Medicine;10/16/2012, Vol. 157 Issue 8, p533 

    Background: Currently, there is no proven alternative therapy for patients with familial Mediterranean fever (FMF) that is resistant to or intolerant of colchicine, lnterleukin-1 is a key proinflammatory cytokine in FMF. Objective: To assess the efficacy and safety of rilonacept, an...

  • FDA issues Multiple Drug Warnings.  // Travel Medicine Advisor;Aug2011 Supplement, p1 

    The August 2011 issue of the journal "Pharmacology Watch," is presented. It discusses the multiple drug safety warnings from the U.S. Food and Drug Administration. It offers information on the study conducted by FDA on the possible link between angiotensin receptor blockers (ARBs) and cancer. It...

  • Stronger warning for ED drugs.  // Pharmaceutical Representative;Dec2007, Vol. 37 Issue 12, p16 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the new labeling for a class of erectile dysfunction therapies. The new label highlights the potential risk of sudden hearing loss associated with the drug. The class is known as phosphodiesterase type 5...

  • Effect of dermatologic drugs on pregnancy and lactation. Apgar, Barbara // American Family Physician;2/1/1998, Vol. 57 Issue 3, p544 

    Focuses on the use of dermatologic drugs in pregnant and lactating women, with emphasis on regulations from the United States Food and Drug Administration regulations known as the Pregnancy and Lactation Categories (P&LC) while highlighting a study conducted by B.R. Reed and appeared in the 1997...

  • PRODUCTS & SERVICES.  // Endocrine Today;Jun2010, Vol. 8 Issue 6, p36 

    This section offers news briefs related to endocrinology as of June 2010, including the release of the magazine "Power of Prevention," the approval of aglucosidase alfa by the U.S. Food and Drug Administration (FDA), and the bilingual fact sheet released by the Hormone Foundation.

  • Observations. Formanek Jr., Raymond // FDA Consumer;Jan/Feb2006, Vol. 40 Issue 1, p2 

    The article introduces a series of reports published in the January 2006 issue.

  • Fluoroquinolones: risk of tendinitis and tendon rupture.  // WHO Drug Information;2008, Vol. 22 Issue 3, p200 

    The article reports on the importance of providing a medical caution regarding the health risks of fluoroquinolones. The U.S. Food and Drug Administration (FDA) has required manufacturers of the said drug to indicate information and medication guide in the label for possible side effects and the...

  • Consumer Reports Finds Dangerous Vitamin and Herbal Products Sold Over the Counter. Napoli, Maryann // HealthFacts;May2004, Vol. 29 Issue 5, p5 

    Focuses on the health dangers posed by several vitamins or herbs classified by the U.S. Food and Drug Administration as dietary supplements. Information on ingredients that are linked to serious adverse events; Role of the Web-based organization ConsumerLab.com as a testing service for...

  • CONGRESS ACTS ON DRUG SAFETY--TOO LITTLE, TOO LATE.  // HealthFacts;Oct2007, Vol. 32 Issue 10, p4 

    The author discusses the legislation requiring a portion of user fee to be used in monitoring the safety of new drugs in the U.S. According to the author, the legislation does not make the FDA any better in protecting consumers from the harmful effects of drugs. He states that consumers should...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics